Clinical trial NCT02936973: Catgut Implantation at Acupoints for the Treatment of Simple Obesity
Official title: Clinical Effect of Catgut Implantation at Acupoints for the Treatment of Simple Obesity: a Multicentre Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Obesity
Keywords: simple obesity
catgut implantation
Lead sponsor: Hubei Hospital of Traditional Chinese Medicine
Sponsor class: OTHER
Collaborators: name: State Administration of Traditional Chinese Medicine of the People's Republic of China
name: Dongzhimen Hospital, Beijing
name: The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine
First posted: 2016-10-18
Enrollment: 216
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The primary objective of this multicenter randomized controlled trial is to evaluate treatment effectiveness of intervening simple obesity people with catgut implantation at preferred acupoints, which excludes placebo effect; the secondary objective is to evaluate safety and superiority of treating simple obesity with catgut implantation at acupoints to provide high-level evidence for it clinically.

Detailed description: This randomized, double-blind sham-controlled clinical trial will be conducted at Hubei Provincial Hospital of TCM, Dongzhimen Hospital Beijing University of Chinese Medicine and the First Hospital of Hunan University of Chinese Medicine. This study includes the following time points: a treatment period of 16 weeks after screening and a follow-up period of 24 weeks. The total study period will be 40 weeks. All patients will be randomized into the real catgut implantation at acupoints group or the sham catgut implantation at acupoints group.The primary outcome measurement of this study is the rate of waistline reduction compared with baseline. The secondary outcome measurements are the rate of reduction of weight, BMI, hipline, WHR and PBF, and changes in the IWQOL-Lite compared with baseline. These parameters will be evaluated at week 0, week 4, week 8, week 12, week 16, week 28 and week 40. Changes in SF-36, HAD and SES compared with baseline will be evaluated at week 0, week 16 and week 40. SF-36 and IWQOL-Lite will be used to evaluate obese patient quality of life. HAD and SES will be used to evaluate psychological status. In addition, hepatorenal function, blood fat, liver bladder spleen colour ultrasound, FBG and insulin concentration will be used to evaluate whether catgut implantation at acupoints can improve the physiological function of obese patients.

Eligibility criteria: Inclusion criteria

Patients recruited for this study should meet the following inclusion criteria:

1. meeting the diagnosis standard for simple obesity in Redefinition and Processing of Obesity in Asia \& Pacific Area released by WHO in February 2000;
2. age: 18-45;
3. BMI: 25≤BMI\<30;
4. waistline: males ≥95 cm; females ≥85 cm;
5. smokers have not changed their smoking habits for at least 2 months;
6. willing to accept the above-described intervention methods.

Exclusion criteria

Patients with any of the following criteria will be excluded from the study:

1. endocrine disease (such as polycystic ovarian syndrome, Cushing's Disease, and hypothyroidism, among others);
2. gestational diabetes or uncontrolled hypertension (SBP ≥160 mmHg; DBP ≥100 mmHg) \[23\], or lung, heart, liver or kidney disease;
3. nervous system disease or mental disorders, history of hospitalized depression, two instances of paralepsy or suicidal tendency;
4. history of clinical diagnosis of an eating disorder , such as bulimia or cynorexia, anorexia; or weight changes greater than 5 kg in the previous 3 months;
5. history of weight loss with surgery or a history of post-operative adhesion;
6. having taken drugs with a known influence on weight or appetite in the previous 3 months, such as diet pills, corticosteroid drugs, anti-depression drugs, diazepam drugs, nonselective body antihistamine, nicotine replacements, or hypoglycaemic drugs, or planning to give up smoking and drinking;
7. pregnancy, lactation, or planning to become pregnant within 40 weeks;
8. received catgut implantation at acupoints;
9. participated in clinical research on obesity in the previous 3 months ;
10. protein allergy and scars;
11. skin disease such as eczema and psoriasis;
12. coagulation disorders, taking warfarin, heparin or other anticoagulant drugs;
13. not cooperative or cannot maintain treatment during the study period.

Primary outcomes:
measure: the rate of waistline reduction compared with baseline
timeFrame: week4 ,week8,week12,week16,week28,week40.
Secondary outcomes:
measure: the rate of reduction of weight compared with baseline
timeFrame: week4 ,week8,week12,week16,week28,week40.
measure: the rate of reduction of body mass index compared with baseline
timeFrame: week4 ,week8,week12,week16,week28,week40.
measure: the rate of reduction of hipline compared with baseline
timeFrame: week4 ,week8,week12,week16,week28,week40.
measure: the rate of reduction of waist-hip ratio compared with baseline
timeFrame: week4 ,week8,week12,week16,week28,week40.
measure: the rate of reduction of percentage of body fat compared with baseline
timeFrame: week4 ,week8,week12,week16,week28,week40.
measure: changes in IWQOL - Lite scale score compared with baseline
timeFrame: week4 ,week8,week12,week16,week28,week40.
measure: changes in SF - 36 life quality scale score compared with baseline
timeFrame: week4 ,week16,week40.
measure: changes in HAD scale score compared with baseline
timeFrame: week4 ,week16,week40.
measure: changes in self-esteem scale score compared with baseline
timeFrame: week4 ,week16,week40.
measure: changes in serum total cholesterol compared with baseline
timeFrame: week16.
measure: changes in serum triglyceride compared with baseline
timeFrame: week16.
measure: changes in low-density lipoprotein cholesterol (LDL-C) compared with baseline
timeFrame: week16.
measure: changes in High-density lipoprotein cholesterol(HDL-C) compared with baseline
timeFrame: week16.
measure: changes in fasting blood-glucose （FBG）compared with baseline
timeFrame: week16.
measure: changes in fasting insulin ( FINS) compared with baseline
timeFrame: week16.
measure: The adverse effects of catgut implantation at acupoints and as measured by number of participants with adverse events.
timeFrame: from week 2 to week 16.
Other outcomes:
Locations:
city: Wuhan
country: China
facility: Hubei Provincial Hospital of Traditional Chinese Medicine
state: Hubei
Study officials:
affiliation: Hubei Hospital of Traditional Chinese Medicine
name: Zhongyu Zhou, Professor
role: PRINCIPAL_INVESTIGATOR
References:
citation: Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF, RIO-Diabetes Study Group. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet. 2006;368:1660-72. Preljevic VT, Østhus TB, Sandvik L, Opjordsmoen S, Nordhus IH, Os I, et al. Screening for anxiety and depression in dialysis patients: comparison of the Hospital Anxiety and Depression Scale and the Beck Depression Inventory. J Psychosom Res. 2012;73:139-44. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rössner S, RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant onweight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet. 2005;365:1389-97. Rosenberg M. Society and the adolescent self-image. Princeton, NJ: Princeton University Press; 1965. World Health Organization, Regional Office for the Western Pacific. The Asia-Pacific perspective: redefining obesity and its treatment. Sydney: Health Communications Australia; 2000. Astrup A, Madsbad S, Breum L, Jensen TJ, Kroustrup JP, Larsen TM. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:1906-13. MacPherson H, White A, Cummings M, Jobst KA, Rose K, Niemtzow RC, et al. Standards for reporting interventions in controlled trials of acupuncture: the STRICTA recommendations. J Altern Complement Med. 2002;8:85 - 9. Ralph JL, Von Ah D, Scheett AJ, Hoverson BS, Anderson CM. Diet assessment methods: a guide for oncology nurses. Clin J Oncol Nurs. 2011;15:E114 - 21. James WP, Astrup A, Finer N, Hilsted J, Kopelman P, Rössner S, et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance Lancet. 2000;356:2119-25.
citation: Chen X, Huang W, Wei D, Zhao JP, Zhang W, Ding DG, Jiao Y, Pan HL, Zhang JJ, Zhong F, Gao F, Jin YT, Zheng YW, Zhang YJ, Huang Q, Zeng XT, Zhou ZY. Effect of Acupoint Catgut Embedding for Middle-Aged Obesity: A Multicentre, Randomised, Sham-Controlled Trial. Evid Based Complement Alternat Med. 2022 Feb 27;2022:4780019. doi: 10.1155/2022/4780019. eCollection 2022.
citation: Chen X, Huang W, Wei D, Ding DG, Jiao Y, Pan HL, Jin YT, Zheng YW, Zhang YJ, Zhang YR, Liu YR, Zhou ZY. Clinical effect of catgut implantation at acupoints for the treatment of simple obesity: A multicentre randomized controlled trial. Medicine (Baltimore). 2020 Nov 25;99(48):e23390. doi: 10.1097/MD.0000000000023390.